New drug combo targets Hard-to-Treat cancers in early trial

NCT ID NCT05856981

First seen Jan 04, 2026 · Last updated Apr 28, 2026 · Updated 17 times

Summary

This early-phase study tests a new drug called ADU-1805, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and how the drug moves through the body. About 130 participants will take part across multiple centers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Gabrail Cancer & Research Center

    RECRUITING

    Canton, Ohio, 44718, United States

    Contact

  • Grand Hopital de Charleroi (GHdC) - Hopital Notre Dame

    RECRUITING

    Charleroi, Belgium

    Contact

  • Henry Ford Cancer Institute

    RECRUITING

    Detroit, Michigan, 48202, United States

    Contact

  • Hosp 12 de Octubre

    RECRUITING

    Madrid, Spain

    Contact

  • Hospital General Universitario Gergorio Maranon

    RECRUITING

    Madrid, Spain

    Contact

  • Virginia Cancer Specialists

    RECRUITING

    Fairfax, Virginia, 22205, United States

    Contact

  • Washington University Medical Campus

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

Conditions

Explore the condition pages connected to this study.